ライフサイエンスコーパス: malignant pleural mesothelioma

1 driven by the complex genomic background of malignant pleural mesothelioma.

2 ients with measurable relapsed or refractory malignant pleural mesothelioma.

3 ) identified 68 with advanced ASS1-deficient malignant pleural mesothelioma.

4 our activity in patients with PD-L1-positive malignant pleural mesothelioma.

5 ne depletion in patients with ASS1-deficient malignant pleural mesothelioma.

6 nded as a therapy for patients with advanced malignant pleural mesothelioma.

7 VAT-PP and talc pleurodesis in patients with malignant pleural mesothelioma.

8 idered the best available serum biomarker of malignant pleural mesothelioma.

9 veral control groups and 1,026 patients with malignant pleural mesothelioma.

10 acy of trimodality therapy in stage I to III malignant pleural mesothelioma.

11 rging therapeutic option in the treatment of malignant pleural mesothelioma.

12 atment with cisplatin alone in patients with malignant pleural mesothelioma.

13 e extent of disease in patients with diffuse malignant pleural mesothelioma.

14 s promise in the palliation of patients with malignant pleural mesothelioma.

15 d with nintedanib or placebo in unresectable malignant pleural mesothelioma.

16 t options exist for second-line treatment of malignant pleural mesothelioma.

17 treatments in relapsed mesothelin-expressing malignant pleural mesothelioma.

18 Patients with malignant pleural mesothelioma, a rapidly progressing ma

19 unresectable locally advanced or metastatic malignant pleural mesothelioma, an Eastern Cooperative O

20 Patients with measurable advanced malignant pleural mesothelioma and disease progression a

21 ed >=18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance stat

22 y of trimodality therapy in the treatment of malignant pleural mesothelioma and identify prognostic f

23 AR-T cell engineering strategy in a model of malignant pleural mesothelioma and validate our findings

24 s, spontaneous pneumothorax in patients with malignant pleural mesotheliomas and primary lung tumors,

25 val in patients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis mig

26 Treatment options for malignant pleural mesothelioma are scarce.

27 t of biomarkers for tazemetostat activity in malignant pleural mesothelioma beyond BAP1 inactivation

28 am of the type I IGF receptor in a subset of malignant pleural mesothelioma cell lines and determined

29 Here, we report the data of a large malignant pleural mesothelioma cohort within a (68)Ga-FA

30 d report here on the interim analysis of the malignant pleural mesothelioma cohort.

31 ute, day 1, every 3 wk) for the treatment of malignant pleural mesothelioma did not result in surviva

32 sor gene in diverse cancer types, notably in malignant pleural mesothelioma (DPM), and has also been

33 409 patients with malignant pleural mesothelioma, from 76 centres in the U

34 urvival and quality of life in patients with malignant pleural mesothelioma have, to our knowledge, n

35 Malignant pleural mesothelioma incidence continues to ri

36 published literature of clinical studies in malignant pleural mesothelioma, including phase II trial

37 Malignant pleural mesothelioma is a highly aggressive ca

38 Malignant pleural mesothelioma is a relatively uncommon

39 Malignant pleural mesothelioma is almost always fatal, a

40 Malignant pleural mesothelioma is an aggressive malignan

41 Malignant pleural mesothelioma is an aggressive primary

42 ic cell-based immunotherapy in patients with malignant pleural mesothelioma is feasible, well-tolerat

43 The incidence of malignant pleural mesothelioma is increasing throughout

44 ling and dishevelled (Dvl) overexpression in malignant pleural mesothelioma (MM).

45 me recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, ye

46 Malignant pleural mesothelioma (MPM) carries a poor prog

47 gulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compa

48 target for TTFields, we applied TTFields to malignant pleural mesothelioma (MPM) cells forming TNTs

49 ment (TME) in paraffin tumor tissues such as malignant pleural mesothelioma (MPM) could yield insight

50 Malignant pleural mesothelioma (MPM) expresses high leve

51 Malignant pleural mesothelioma (MPM) has an overall poor

52 c or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespre

53 Delineation of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind o

54 Malignant pleural mesothelioma (MPM) has relatively inef

55 Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited t

56 Malignant pleural mesothelioma (MPM) is a deadly disease

57 Malignant pleural mesothelioma (MPM) is a disease of inc

58 Malignant pleural mesothelioma (MPM) is a highly aggress

59 Malignant pleural mesothelioma (MPM) is a highly aggress

60 Malignant pleural mesothelioma (MPM) is a highly lethal,

61 Malignant pleural mesothelioma (MPM) is a rare malignanc

62 Malignant pleural mesothelioma (MPM) is a rare malignanc

63 Malignant pleural mesothelioma (MPM) is a rare, aggressi

64 Malignant pleural mesothelioma (MPM) is a rare, but aggr

65 Malignant pleural mesothelioma (MPM) is an aggressive ca

66 Malignant pleural mesothelioma (MPM) is an aggressive ca

67 Malignant pleural mesothelioma (MPM) is an aggressive ca

68 Malignant pleural mesothelioma (MPM) is an aggressive hu

69 Malignant pleural mesothelioma (MPM) is an aggressive ma

70 Malignant pleural mesothelioma (MPM) is an aggressive ne

71 Malignant pleural mesothelioma (MPM) is an aggressive th

72 Human malignant pleural mesothelioma (MPM) is considered a rar

73 Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an

74 Malignant Pleural Mesothelioma (MPM) is typically diagno

75 d pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell l

76 Outcomes of localized malignant pleural mesothelioma (MPM) remain poor despite

77 spectrometry (LA-ICP-TOFMS) to analyze human malignant pleural mesothelioma (MPM) samples at the cell

78 = 99) and targeted exomes (n = 103) from 216 malignant pleural mesothelioma (MPM) tumors.

79 lso retrained and tested in 28 patients with malignant pleural mesothelioma (MPM) who underwent lung

80 Treatment of malignant pleural mesothelioma (MPM) with Ranpirnase (On

81 ated receptor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM ce

82 In Malignant Pleural Mesothelioma (MPM), YAP is activated b

83 plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM).

84 ed symptom burden over time in patients with malignant pleural mesothelioma (MPM).

85 horylase (MTAP) deletion, seen frequently in malignant pleural mesothelioma (MPM).

86 y, we measured tumor volume in patients with malignant pleural mesothelioma (MPM).

87 ectomy (EPP) in the treatment of epithelioid malignant pleural mesothelioma (MPM).

88 ve efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM).

89 nd gemcitabine have single-agent activity in malignant pleural mesothelioma (MPM).

90 se (RTK) has not been extensively studied in malignant pleural mesothelioma (MPM).

91 rug combination exclusively in patients with malignant pleural mesothelioma (MPM).

92 tal exposure to FE fibers is correlated with malignant pleural mesothelioma (MPM).

93 s chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM).

94 ge to undergoing cancer-directed surgery for malignant pleural mesothelioma (MPM); however, it is unc

95 The pathological distinction between malignant pleural mesothelioma (MPM)and adenocarcinoma (

96 ich has been shown to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in s

97 6 non-small-cell lung cancer (NSCLC), and 71 malignant pleural mesotheliomas (MPM).

98 NA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present i

99 Malignant pleural mesotheliomas (MPMs) often show CDKN2A

100 ough SV40 oncoproteins have been detected in malignant pleural mesotheliomas (MPMs), their role in th

101 le patients were aged 18 years or older with malignant pleural mesothelioma of any histology that was

102 and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis.

103 stable disease) at week 12 in patients with malignant pleural mesothelioma per protocol with BAP1 in

104 Ten patients with malignant pleural mesothelioma received metronomic cyclo

105 prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, an

106 Our previous microarray analysis of malignant pleural mesothelioma revealed alterations in c

107 key signaling pathways of the IGF system in malignant pleural mesothelioma specimens.

108 efore, IGF system components represent novel malignant pleural mesothelioma therapeutic targets for i

109 e clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 stud

110 hat multiple mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis.

111 fulness of (18)F-FDG-CI in the assessment of malignant pleural mesothelioma using histopathology as t

112 in part 2 in patients with BAP1-inactivated malignant pleural mesothelioma was 54% (95% CI 42-67; 33

113 nty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male pa

114 viously treated patients with PD-L1-positive malignant pleural mesothelioma were enrolled from 13 cen

115 Despite several attempts at treating malignant pleural mesothelioma with various modalities,

116 Our data suggest that in malignant pleural mesothelioma, Wnt signaling is activat